FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/05/087047 [Registered on: 16/05/2025] Trial Registered Prospectively
Last Modified On: 15/05/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Homeopathy 
Study Design  Single Arm Study 
Public Title of Study   An interventional clinical trial to see effect of homoeopathic medicine in reproductive age group female with abnormal uterine bleeding 
Scientific Title of Study   EFFECT OF INDIVIDUALIZED HOMOEOPATHIC MEDICINES IN FIFTY MILLESIMAL POTENCY IN ABNORMAL UTERINE BLEEDING WITH IT’S MIASMATIC ANALYSIS IN REPRODUCTIVE AGE GROUP FEMALES: A PROSPECTIVE STUDY 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Nayab Amir 
Designation  Postgraduate Trainee 
Affiliation  The Calcutta Homoeopathic Medical College and Hospital 
Address  Dept. Of Organon of Medicine, OPD room no. 19, The Calcutta Homoeopathic Medical College and Hospital 265,266 Acharya Prafulla Chandra Road Kolkata

Kolkata
WEST BENGAL
700009
India 
Phone  7980360307  
Fax    
Email  nayabamir55@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Aloke Kumar Ghosh 
Designation  Professor and head 
Affiliation  The Calcutta Homoeopathic Medical College and Hospital 
Address  Dept. Of Organon of Medicine, OPD room no. 19, The Calcutta Homoeopathic Medical College and Hospital 265,266 Acharya Prafulla Chandra Road Kolkata

Kolkata
WEST BENGAL
700009
India 
Phone  9836584268  
Fax    
Email  dralok1974ghosh@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Nayab Amir 
Designation  Postgraduate Trainee 
Affiliation  The Calcutta Homoeopathic Medical College and Hospital 
Address  Dept. Of Organon of Medicine, OPD room no. 19, The Calcutta Homoeopathic Medical College and Hospital 265,266 Acharya Prafulla Chandra Road Kolkata

Kolkata
WEST BENGAL
700009
India 
Phone  7980360307  
Fax    
Email  nayabamir55@gmail.com  
 
Source of Monetary or Material Support  
The Calcutta Homoeopathic Medical College and Hospital,265,266 Acharya Prafulla Chandra Road Kolkata 700009, West Bengal  
 
Primary Sponsor  
Name  The Calcutta Homoeopathic Medical College and Hospital 
Address  265,266 Acharya Prafulla Chandra Road Kolkata 700009, West Bengal  
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Nayab Amir  The Calcutta Homoeopathic Medical College and Hospital  265, 266, Acharya Prafulla Chandra Road, Kolkata 700009, West Bengal
Kolkata
WEST BENGAL 
7980360307

nayabamir55@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
The Institutional Ethical Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: N939||Abnormal uterine and vaginal bleeding, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Individualized homoeopathic medicines in fifty millesimal potency with concomitant care.  Intervention was planned as administering indicated homeopathic medicines in 50 millesimal potencies, as decided appropriate to the case or condition. In 50 millesimal potencies, one medicated globule of no.10 is to be dissolved in 100 ml of distilled water, 5 minims of rectified spirit are added to it and mixed well to make 7 doses or as required. After 10 uniform forceful downward strokes to the vial, each dose of 15ml is to be added in 45ml normal water in a clean cup and to be stirred well, from the mixture 5ml is to be taken orally on clean tongue in empty stomach, and rest of the mixture is to be discarded. Dosage and repetition will be done depending upon the individual requirement of the case. 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  49.00 Year(s)
Gender  Female 
Details  1) Patients fitting in the definition of AUB cases [(ICD-11-GA2Y)] more than 6 months.
2) Patients with age varying from 18 to 49 years.
3) Patients who can read or understand English, Bengali, Hindi.  
 
ExclusionCriteria 
Details  1) Patient not willing to participate in study.
2) Pregnant, Puerperal women, Lactating mothers.
3) Patients having IUCD in situ.
4) Non-menstrual & non uterine causes for bleeding (Foreign bodies, genital malignancy,
abortion, post coital).
5) Patients having haemoglobin less than 8 gm/dl [44].
6) Patients already undergoing any other treatment for AUB or any chronic diseases especially
in last 6 weeks.
7) Patients already diagnosed of unstable psychiatric illness or other systemic diseases
affecting quality of life.
8) Patients having any habits of substance abuse and addiction.
9) Simultaneous participation in any other clinical trial.  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To see changes in Pictorial Blood Assessment Chart (PBAC) Score after 6 months
of intervention.  
At baseline, every 4 weeks, up to 6 months 
 
Secondary Outcome  
Outcome  TimePoints 
1. To detect the predominant miasm in cases with Abnormal uterine bleeding (AUB).
2. Changes in Short Form-36 Health Survey Questionnaire 1.0.
3. To ascertain and shortlist the most frequently indicated homoeopathic medicines in
the treatment of AUB.  
At baseline, every 4 weeks, up to 6 months 
 
Target Sample Size   Total Sample Size="34"
Sample Size from India="34" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   29/05/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Abnormal uterine bleeding (AUB;ICD-11-GA2Y) is a most common gynaecological symptom that describes irregularities in the menstrual cycle involving frequency, regularity, duration, and volume of flow outside of pregnancy. A normal menstrual cycle has a frequency of 24 to 38 days and lasts 2 to 7, with 5 to 80 millilitres of blood loss. Variations in any of these 4 parameters constitute abnormal uterine bleeding. It encompasses heavy menstrual bleeding, irregular menstrual bleeding and intermenstrual bleeding. Among them, HMB is the common conditions which affects 14-25% of women of reproductive age, with menorrhagia as the most common presentation about 32% followed by polymenorrhoea in 14%, metrorrhagia in 9% and menometrorrhagia in 4% of patients. AUB accounts for one third of outpatients who visits gynaecology OPD. This open label, single arm, prospective study is aimed to evaluate the role of Individualised Homoeopathic Medicines (IHMS) in fifty millesimal scale in the management of abnormal uterine bleeding in reproductive age group females(18 to 49 years). Study is planned to be conducted at The Calcutta Homoeopathic Medical College and Hospital. Study has a target to achieve a sample of 34 patients. Primary outcome assessment will be done by using PBAC Score and secondary outcome is to see changes in Short Form-36 Health Survey Questionnaire 1.0; to detect the predominant miasm in cases with Abnormal uterine bleeding (AUB); and to  shortlist the most frequently indicated homoeopathic medicines in the treatment of AUB; all to be measured at baseline, and every month up to 6 months. The score obtained by the patients will be compared and result will be analysed as per appropriate statistical methods and interference will be done thereafter. 
Close